Navigation Links
Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors
Date:4/15/2008

GLASGOW, Scotland, April 15 /PRNewswire/ -- Excalibur, the new international investment house launched by Sir Christopher Evans, today (Tuesday) welcomed the sale of PIramed to Roche.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 )

The sale of PIramed to Roche for $185 million means a 'very substantial cash return' to investors in Merlin III, the investment fund created by Sir Christopher five years ago.

Merlin Biosciences were co-founding investors in PIramed at the outset in 2003 with JP Morgan. Merlin, with the founders of the company, also selected the CEO, the management team, built the board of directors and continued to provide ongoing funding and strategic advice to the company.

Sir Christopher Evans said: "The sale is terrific news for everyone who has been associated with PIramed since the early days. It is complete vindication of the founders' vision and also the flawless execution of a scientific, management and investment plan that Merlin and JP Morgan stuck to from the outset. We are delighted to have been involved from day one and at Excalibur we are pleased to be delivering to investors in our Merlin Fund III such a substantial return on their investment."

Notes to Editors:

Excalibur has been founded by Professor Sir Christopher Evans and is a major new development of the original Merlin Biosciences business. Merchant Ventures, a specialist financial services group, was acquired to create Excalibur.

Excalibur is following the successful investment strategy of Merlin's Fund III which has focused more broadly on healthcare and medical science investments and is already delivering significant returns to investors with five more years to run.

The three existing Merlin investment funds operate under their original titles within the Excalibur group.

Key investors and stakeholders in Excalibur besides Sir Chris include Sir Tom Hunter's West Coast Capital, Professor Jeremy Stone, chairman of Merchant Ventures, and Lloyds TSB.

Further information:

Ramsay Smith,

Media House International.

Tel +44(0)207-397-8460/+44(0)7788-414856.

Email:ramsay@mediahouse.co.uk


'/>"/>
SOURCE Excalibur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
2. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
3. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
4. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
5. Guava Technologies Celebrates Tenth Anniversary
6. New Enterprise Forum Celebrates 22nd Anniversary, Presents Annual Entrepreneur Awards to Randal Charlton & Others
7. Winnick Family Clinical Research Center Celebrates 6th Anniversary
8. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
9. HCM Announces Substantial Growth in 2007
10. Cystic Fibrosis Trial In Children Returns Positive Data
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):